A review of the clinical progress on helminths and their derivative products in autoimmune disease.
- Author:
Xinyue WU
1
;
Hongyu GAO
2
;
Shuyao DUAN
1
;
Wenbo DING
1
;
Xiaodi YANG
3
Author Information
1. Anhui Provincial Key Laboratory of Infection and Immunity, Bengbu 233030, China.
2. Anhui Provincial Key Laboratory of Infection and Immunity, Department of Pediatrics, First Affiliated Hospital of Bengbu Medical College, Bengbu 233030, China.
3. Anhui Provincial Key Laboratory of Infection and Immunity, Department of Microbiology and Parasitology, Bengbu Medical College, Bengbu 233030, China. *Corresponding author, E-mail: yxd_qf@163.com.
- Publication Type:Journal Article
- MeSH:
Animals;
Humans;
Autism Spectrum Disorder;
Autoimmune Diseases/drug therapy*;
Helminths;
Inflammatory Bowel Diseases
- From:
Chinese Journal of Cellular and Molecular Immunology
2023;39(12):1132-1140
- CountryChina
- Language:Chinese
-
Abstract:
Traditional medications used for treating autoimmune diseases often come with a wide range of adverse effects. Current treatments focus mainly on symptom management, resulting in significant health issues and financial burdens for patients. Recently, clinical research has demonstrated the potential of helminths and their derivatives as effective therapies for autoimmune disorders. Helminths, being a near-natural immunomodulator, exhibit milder effects than broad-spectrum immunosuppressants and corticosteroids, thereby presenting a promising alternative for the treatment of autoimmune diseases. However, different helminths' therapeutic efficacy and mechanisms and their derivatives in treating autoimmune diseases may vary. Therefore, we aim to review recent clinical advancements in the use of helminths and their derivatives for treating inflammatory bowel disease, multiple sclerosis, and autism spectrum disorder, with a view to offering novel clinical treatment approaches.
